Early detection of disease progression could facilitate significant improvement in patient outcomes, as approximately 25–30% of NSCLC patients failing ALK or EGFR TKI miss subsequent therapy or chemotherapy due to rapid clinical deterioration37,38. Here, ALK is linked to non-small cell lung carcinoma.